Journal article icon

Journal article

Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma

Abstract:

Background

Aiming to improve treatment options for BRAF wild-type melanoma, we previously conducted the DOC-MEK study of docetaxel with MEK inhibitor (MEKi) selumetinib or placebo, revealing trends to prolongation of progression-free survival (hazard ratio 0.75, P = 0.130), and improved response rates (32% vs 14%, P = 0.059) with docetaxel plus selumetinib. NRAS status did not associate with outcome. Here, the aim was to identify novel biomarkers of response to MEKi...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1038/s41416-019-0673-5

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Willenbrock, F More by this author
Hodgson, DR More by this author
Expand authors...
Cancer Research UK More from this funder
Publisher:
Springer Nature Publisher's website
Journal:
British Journal of Cancer Journal website
Volume:
122
Issue:
4
Pages:
506-516
Publication date:
2020-02-18
Acceptance date:
2019-11-15
DOI:
EISSN:
1532-1827
ISSN:
0007-0920
Pmid:
31839677
Pubs id:
1078864
Local pid:
pubs:1078864
Language:
English
Keywords:
Format:
Print-Electronic

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP